Create an account or log in to participate in this activity
This activity was planned in collaboration with the Federation of State Medical Boards.
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Contact Hours: 3.0, of which 3.0 are eligible for pharmacology credit
This program meets the criteria of the Massachusetts Board of Registration in Medicine for risk management study and opioid education. Several states have similar requirements. Please check with your Board to determine if this activity will fulfill your state's specific requirements.
This program meets the criteria of the Massachusetts Board of Registration in Medicine for risk management study.
This program meets the criteria of the Massachusetts Board of Registration in Medicine for opioid education.
The AAFP has reviewed SCOPE of Pain: Safer/Competent Opioid Prescribing Education and deemed it acceptable for up to 3.0 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 10/01/2023 to 10/01/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
By participating in the activity and claiming credit, you grant the Center for Continuing Education permission to submit your information to the ACCME, the conduit to the ABS.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate and de-identified data is shared with the commercial supporters.
This activity is approved for 3.0 CPE credit(s) under the ACPE universal activity number JA0000185-0000-23-012-H08-P. The activity is available for credit claiming for up to 60 days after completion of the activity.
Through the American Board of Medical Specialties (ABMS) ongoing commitment to increase access to practice relevant Maintenance of Certification (MOC) Activities through the ABMS Continuing Certification Directory, SCOPE of Pain has met the requirements as an MOC Part II Self-Assessment and/or MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
Note: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board's general CME requirement (only). Please refer directly to your Member Boards' MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
In order to receive credit, participants must review the activity content (six podcast episodes) and complete the post-test and evaluation. Participants who receive a grade of 70% or greater on the post-tests will receive credit. There will also be an online follow-up survey that will be distributed two months after completion of the program in order to further measure participants? changes in knowledge and behavior.
Date of original release: 10/1/2023
Date of most recent review: 10/1/2023
Date of expiration: 9/30/2024
Physicians, nurse practitioners, registered nurses, physician assistants, nurses, dentists, pharmacists, and allied health professionals whose practices manage acute and chronic pain.
At the conclusion of these activities, participants will be better able to:
For questions about CME, please contact cme@bu.edu.
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
This activity does include discussion of the off-label use of sublingual buprenorphine to treat pain. Sublingual buprenorphine has been FDA approved for addiction treatment but not pain treatment. This presentation does include discussion of the off-label use of clonidine and tizanidine to treat opioid withdrawal symptoms. Clonidine and tizanidine are not FDA approved for this use.
Daniel P. Alford, MD, MPH, FACP
Course Director
Professor of Medicine
Boston University Chobanian & Avedisian School of Medicine
Boston Medical Center
Faculty member has no relevant financial relationships to disclose.
Erica Bial, MD, MS
Interventional Pain Specialist
Sports Medicine North
Peabody, Massachusetts
Faculty member has no relevant financial relationships to disclose.
Patrick Kelly, PharmD
Pharmacist Course Advisor
Senior Lecturer
University of Rhode Island College of Pharmacy
Faculty member has no relevant financial relationships to disclose.
Kristin Wason, MSN, NP-C, CARN
NCPD Course Advisor
Clinical Educator, Massachusetts OBAT TTA
Boston University Chobanian & Avedisian School of Medicine
Boston Medical Center
Faculty member has no relevant financial relationships to disclose.
Ilana Hardesty, MA, Assistant Director, CME Operations, Boston University Chobanian & Avedisian School of Medicine CCE
Brian Jack, MD, independent AAFP reviewer
Patrick Kelly, PharmD, Senior Lecturer, University of Rhode Island College of Pharmacy
Carmela Townsend, DNP, MS/MBA, RN, Lead Nurse Planner, Boston University Chobanian & Avedisian School of Medicine CCE
Jason Worcester, MD, independent CME reviewer
Planning Committee members have no relevant financial relationships to disclose.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
This additional module is required for users licensed in the State of New York: "Managing Pain and Opioid Use: An Educational Program on Compliance with New York State Prescribing Laws."
There is a $25 fee for the NY module.
SCOPE of Pain
© 2024 Trustees of Boston University. Site by Root802.
Overview